As of 2025-12-16, the Relative Valuation of Kymera Therapeutics Inc (KYMR) is (48.88) USD. This relative valuation is based on P/E multiples. With the latest stock price at 85.68 USD, the upside of Kymera Therapeutics Inc based on Relative Valuation is -157.0%.
The range of the Relative Valuation is (20.33) - (77.09) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 3.6x - 13.9x | 8.8x |
| Forward P/E multiples | 3.7x - 14.0x | 8.8x |
| Fair Price | (20.33) - (77.09) | (48.88) |
| Upside | -123.7% - -190.0% | -157.0% |
| Date | P/E |
| 2025-12-15 | -15.43 |
| 2025-12-12 | -16.15 |
| 2025-12-11 | -15.81 |
| 2025-12-10 | -16.18 |
| 2025-12-09 | -15.64 |
| 2025-12-08 | -16.98 |
| 2025-12-05 | -11.99 |
| 2025-12-04 | -11.92 |
| 2025-12-03 | -11.88 |
| 2025-12-02 | -11.57 |
| 2025-12-01 | -12.04 |
| 2025-11-28 | -12.22 |
| 2025-11-26 | -12.22 |
| 2025-11-25 | -11.89 |
| 2025-11-24 | -11.81 |
| 2025-11-21 | -11.89 |
| 2025-11-20 | -11.64 |
| 2025-11-19 | -11.67 |
| 2025-11-18 | -11.58 |
| 2025-11-17 | -11.54 |
| 2025-11-14 | -11.69 |
| 2025-11-13 | -11.46 |
| 2025-11-12 | -11.44 |
| 2025-11-11 | -11.41 |
| 2025-11-10 | -11.03 |
| 2025-11-07 | -10.56 |
| 2025-11-06 | -10.98 |
| 2025-11-05 | -10.78 |
| 2025-11-04 | -10.79 |
| 2025-11-03 | -10.75 |
| 2025-10-31 | -11.13 |
| 2025-10-30 | -11.06 |
| 2025-10-29 | -10.81 |
| 2025-10-28 | -11.15 |
| 2025-10-27 | -10.96 |
| 2025-10-24 | -10.54 |
| 2025-10-23 | -10.40 |
| 2025-10-22 | -10.05 |
| 2025-10-21 | -10.50 |
| 2025-10-20 | -10.89 |
| 2025-10-17 | -10.77 |
| 2025-10-16 | -10.89 |
| 2025-10-15 | -11.32 |
| 2025-10-14 | -10.49 |
| 2025-10-13 | -10.78 |
| 2025-10-10 | -10.30 |
| 2025-10-09 | -10.27 |
| 2025-10-08 | -10.13 |
| 2025-10-07 | -10.25 |
| 2025-10-06 | -10.36 |